Abstract

The gram-negative bacillus Burkholderia pseudomallei is a saprophyte and the cause of melioidosis. Natural infection is most commonly reported in northeast Thailand and northern Australia but also occurs in other parts of Asia, South America, and the Caribbean. Melioidosis develops after bacterial inoculation or inhalation, often in relation to occupational exposure in areas where the disease is endemic. Clinical infection has a peak incidence between the fourth and fifth decades; with diabetes mellitus, excess alcohol consumption, chronic renal failure, and chronic lung disease acting as independent risk factors. Most affected adults ( approximately 80%) in northeast Thailand, northern Australia, and Malaysia have >/=1 underlying diseases. Symptoms of melioidosis may be exhibited many years after exposure, commonly in association with an alteration in immune status. Manifestations of disease are extremely broad ranging and form a spectrum from rapidly life-threatening sepsis to chronic low-grade infection. A common clinical picture is that of sepsis associated with bacterial dissemination to distant sites, frequently causing concomitant pneumonia and liver and splenic abscesses. Infection may also occur in bone, joints, skin, soft tissue, or the prostate. The clinical symptoms of melioidosis mimic those of many other diseases; thus, differentiating between melioidosis and other acute and chronic bacterial infections, including tuberculosis, is often impossible. Confirmation of the diagnosis relies on good practices for specimen collection, laboratory culture, and isolation of B. pseudomallei. The overall mortality rate of infected persons is 50% in northeast Thailand (35% in children) and 19% in Australia.

Highlights

  • B. pseudomallei has been designated a select agent by the U.S Centers for Disease Control and Prevention (CDC)

  • Interest in this organism has been fueled by the establishment of Regional Centers of Excellence across the United States, funded by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) for research into emerging infectious diseases and biothreat organisms

  • The number of investigators who are working on strains of B. pseudomallei is growing, and research laboratories require clearly defined readiness guidelines in the event that one or more persons require postexposure prophylaxis (PEP)

Read more

Summary

Introduction

B. pseudomallei has been designated a select agent by the U.S Centers for Disease Control and Prevention (CDC) (www.cdc.gov/od/sap). If you don’t have time to search the Internet for the latest developments that might impact your work environment, you just might find some of this information in the “Capsule” column. Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.